One milestone after another: Pleco Therapeutics hopes to bring improved cancer treatment to market soon
Acute Myeloid Leukaemia (AML) and Small-Cell Lung Cancer (SCLC) are rare diseases, they occur in fewer than one in 2,000 people. For many pharmaceutical companies, this is a reason to not invest in the development of new drugs or treatments. “But not Pleco Therapeutics”, says Gerben de Rijk.